Literature DB >> 25882456

Biologics for psoriasis: a translational research success story.

Mark Lebwohl1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25882456     DOI： 10.1038/jid.2014.549

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  29 in total

Review 1.  Lymphocyte trafficking in psoriasis: a new perspective emphasizing the dermal dendrocyte with active dermal recruitment mediated via endothelial cells followed by intra-epidermal T-cell activation.

Authors:  B J Nickoloff; C E Griffiths
Journal:  J Invest Dermatol       Date:  1990-11       Impact factor: 8.551

Review 2.  The role of immune system in the pathogenesis of psoriasis.

Authors:  O Baadsgaard; G Fisher; J J Voorhees; K D Cooper
Journal:  J Invest Dermatol       Date:  1990-11       Impact factor: 8.551

Review 3.  Cyclosporine A in the treatment of psoriasis: a clinical and mechanistic perspective.

Authors:  C E Griffiths; J J Voorhees
Journal:  J Invest Dermatol       Date:  1990-11       Impact factor: 8.551

4.  Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

Authors:  Kim A Papp; Craig Leonardi; Alan Menter; Jean-Paul Ortonne; James G Krueger; Gregory Kricorian; Girish Aras; Juan Li; Chris B Russell; Elizabeth H Z Thompson; Scott Baumgartner
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

5.  A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.

Authors:  Gerald G Krueger; Kim A Papp; Dow B Stough; Keith H Loven; Wayne P Gulliver; Charles N Ellis
Journal:  J Am Acad Dermatol       Date:  2002-12       Impact factor: 11.527

6.  A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.

Authors:  Kristian Reich; Richard G Langley; Kim A Papp; Jean-Paul Ortonne; Kristina Unnebrink; Martin Kaul; Joaquin M Valdes
Journal:  N Engl J Med       Date:  2011-10-27       Impact factor: 91.245

Review 7.  Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis.

Authors:  Francesca Chamian; James G Krueger
Journal:  Curr Opin Rheumatol       Date:  2004-07       Impact factor: 5.006

Review 8.  The IL-23/Th17 axis in the immunopathogenesis of psoriasis.

Authors:  Antonella Di Cesare; Paola Di Meglio; Frank O Nestle
Journal:  J Invest Dermatol       Date:  2009-03-26       Impact factor: 8.551

9.  Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis.

Authors:  S L Gottlieb; P Gilleaudeau; R Johnson; L Estes; T G Woodworth; A B Gottlieb; J G Krueger
Journal:  Nat Med       Date:  1995-05       Impact factor: 53.440

10.  A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.

Authors:  Mark Lebwohl; Stephen K Tyring; Tiffani K Hamilton; Darryl Toth; Scott Glazer; Naji H Tawfik; Patricia Walicke; Wolfgang Dummer; Xiaolin Wang; Marvin R Garovoy; David Pariser
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245
View more
  2 in total

Review 1.  Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background.

Authors:  Giulia Ganzetti; Anna Campanati; Elisa Molinelli; Annamaria Offidani
Journal:  World J Cardiol       Date:  2016-02-26

2.  Psoriasis: The Poster Child for Bench-to-bedside Translational Medicine.

Authors:  Lotus Mallbris; Brian J Nickoloff
Journal:  J Clin Aesthet Dermatol       Date:  2015-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.